Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease.

ABSTRACT:

Introduction

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) represents a severe and persistent complication that can arise following allogeneichematopoietic stem cell transplantation (allo-HSCT). This study aimed toassess the effectiveness and safety of basiliximab compared with those of a humanized anti-CD25 monoclonal antibody (xenopax) in the treatment of SR-aGVHD in patients who underwent allo-HSCT.

Methods

This retrospective trial included 32 patients diagnosed with SR-aGVHD who were administered xenopax at 1 mg/kg on days 1, 4, and 8, and weekly thereafter until aGVHD severity was reduced to below grade 2. A historical cohort of 37 patients received basiliximab, which is a chimeric mouse-human anti-CD25 antibody.

Results

The overall response (OR)

SUBMITTER: Zheng X 

PROVIDER: S-EPMC12808378 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature